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Malonate as a ROS product is associated
with pyruvate carboxylase activity in acute
myeloid leukaemia cells
Michelle A. C. Reed1, Christian Ludwig1,3, Christopher M. Bunce2, Farhat L. Khanim2† and Ulrich L. Günther1*†
Abstract
Background: The role of anaplerotic nutrient entry into the Krebs cycle via pyruvate carboxylase has been the
subject of increased scrutiny and in particular whether this is dysregulated in cancer. Here, we use a tracer-based
NMR analysis involving high-resolution 1H-13C-HSQC spectra to assess site-specific label incorporation into a range
of metabolite pools, including malate, aspartate and glutamate in the acute myeloid leukaemia cell line K562. We
also determine how this is affected following treatment with the redeployed drug combination of the lipid-
regulating drug bezafibrate and medroxyprogesterone (BaP).
Results: Using the tracer-based approach, we assessed the contribution of pyruvate carboxylase (PC) vs. pyruvate
dehydrogenase (PDH) activity in the derivation of Krebs cycle intermediates. Our data show that PC activity is
indeed high in K562 cells. We also demonstrate a branched entry to the Krebs cycle of K562 cells with one branch
running counterclockwise using PC-derived oxaloacetate and the other clockwise from the PDH activity. Finally, we
show that the PC activity of K562 cells exclusively fuels the ROS-induced decarboxylation of oxaloacetate to malonate
in response to BaP treatment; resulting in further Krebs cycle disruption via depletion of oxaloacetate and
malonate-mediated inhibition of succinate dehydrogenase (SDH) resulting in a twofold reduction of fumarate.
Conclusions: This study extends the interest in the PC activity in solid cancers to include leukaemias and
further demonstrates the value of tracer-based NMR approaches in generating a more accurate picture of the
flow of carbons and metabolites within the increasingly inappropriately named Krebs cycle. Moreover, our
studies indicate that the PC activity in cancer cells can be exploited as an Achilles heel by using treatments,
such as BaP, that elevate ROS production.
Keywords: Cancer metabolism, Pyruvate carboxylase, AML, Malonate
Background
We have previously demonstrated the individual and
combined anti-proliferative and pro-differentiating ac-
tions of a drug combination termed bezafibrate and
medroxyprogesterone (BaP), consisting of the lipid-
regulating drug bezafibrate (BEZ) and the steroid
contraceptive medroxyprogesterone (MPA) against pri-
mary acute myeloid leukaemia (AML) cells and cell
lines [1–4], Burkitt’s lymphoma (BL) cell lines [5] and
primary chronic lymphocytic leukaemia cells [6]. In
addition, phase II trials of BaP in both AML and BL
have demonstrated in vivo anti-tumour activity in the
absence of toxicity [7, 8] and, in the case of AML, gen-
erated significant haematological responses in some pa-
tients [7].
We previously demonstrated that BaP treatment of
KG1α, K562 and HL60 AML cell lines was associated
with excess generation of reactive oxygen species
(ROS), inducing a range of metabolic changes involving
pathways related to the Krebs cycle, specifically in-
creased succinate/fumarate ratios. The importance of
ROS for novel therapies has also been recognised by
others [9–11] who linked ROS to iron homeostasis [10]
and AKT phosphorylation [11]. Our observations also
implicated direct ROS-mediated chemical conversion
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of metabolites including the conversion of α-
ketoglutarate (α-KG) into succinate and of oxaloacetate
to malonate [4, 12, 13]. Malonate is known to inhibit
succinate dehydrogenase [14], thus interrupting the
conversion of succinate to fumarate.
Here, we present a detailed tracer-based analysis of
metabolism in K562 AML cells with and without expos-
ure to BaP to decipher the origin of malonate and the
relative contributions of pyruvate carboxylase (PC) and
pyruvate dehydrogenase (PDH) activity for the entry of
nutrients into the Krebs cycle. In order to determine
site-specific label incorporations, we used NMR 1H-13C-
HSQC spectra. In such spectra, every signal arises from
a CH group in a metabolite. When acquired with suffi-
ciently high resolution in the 13C-dimension, one can re-
solve couplings arising from adjacent 13C atoms
providing crucial information about site-specific label in-
corporation. Previously, we have used this approach to
study the distribution of 13C-labels arising from [1,2-
13C]glucose and from [3-13C]glutamine in K562 cells
[15]. Here, we have used this analysis to trace the origin
of malonate. Our analysis also sheds new light on pyru-
vate carboxylase activity in cancer cells, an issue that has
been raised in various tumours [16–18].
Methods
Sample preparation
K562 cells were cultured and polar cell extracts were
prepared as described before [4]. For tracer-based meta-
bolic analysis, standard glucose- or glutamine-free
RPMI-1640 media (Gibco) was used and substituted
with 2 g/l [1,2-13C]glucose or 300 mg/l [3-13C]glutamine
(Isotec, Sigma), respectively. 5 × 107 exponentially grow-
ing K562 cells per control or treatment were pelleted by
centrifugation at 8000g for 5 min and resuspended in
the relevant media with BaP or solvent controls and in-
cubated for 24 or 3 h at 37 °C and 5 % CO2 in a humidi-
fied incubator. For BaP treatment, bezafibrate 0.5 mM
and medroxyprogesterone acetate 5 μM (Sigma) or the
equivalent concentrations of DMSO and ethanol solvent
control were added to the media at T = 0 h.
For 3-h labelling of 24-h drug treatments, media was
exchanged for the last 3 h with media supplemented
with labelled glucose or glutamine plus BaP or solvent
control. All samples were dissolved in 100 mM phos-
phate buffer with 10 % D2O and 500 μM Trimethylsilyl-
propanoic acid (TMSP) added.
NMR data acquisition
All spectra were acquired at 298 K on a Bruker
600 MHz spectrometer with a TCI 1.7 mm z-PFG cryo-
genic probe. 1H-13C-HSQC spectra were acquired using
the Bruker sequence hsqcetgpsp.2 with added gradients
during echoes, using 4096 points in the directly
observed dimension for a sweep width of 13 ppm. Four
thousand ninety-six increments, two scans and an inter-
scan delay of 1.5 s were used. The 13C carrier was set to
80 ppm and a spectral width 159.0 ppm was used.
Processing of NMR spectra
All one-dimension spectra were processed using
NMRLab [19] in MATLAB and further analysed using
MetaboLab [20] as described before [4]. In HSQC spec-
tra peaks were picked and assigned in a semi-automated
manner using MetaboLab. To calculate percentage label
incorporations, the cross peaks in labelled spectra and
reference spectra were compared. The 13C isotope con-
stitutes about 1 % of naturally occurring carbon. There-
fore, for more concentrated metabolites, cross peaks
could be seen in the reference spectra. Peak intensities
in control and reference spectra were used to calculate
percentage incorporation of labels into particular car-
bons of metabolites as follows:
The percentage incorporation of 13C into peak X of
metabolite Y in 13C-labelled media % equals 100 N/
(D*S), where % = percentage incorporation, N = intensity
of a signal of a metabolite in labelled media spectrum,
D = intensity of a signal of a metabolite in the control
spectrum, S =mean(ScaleFactor). ScaleFactor(i) = Nr/Dr,
where Nr = intensity of peak i from reference metabolite
in numerator spectrum, Dr = intensity of peak i from ref-
erence metabolite in denominator spectrum.
A reference metabolite was chosen as one of a group
of metabolites that did not change intensity significantly
between BaP and control spectra or between spectra for
enriched and natural abundance media. Results were
similar using myo-inositol, valine, leucine or isoleucine
as the reference metabolite. Labelling was not consid-
ered significantly changed unless BaP treatment changed
percentage label incorporation by a factor of 2.
For signals in spectra arising from [1,2-13C]glucose-
labelled cells that showed CC-couplings, the peak in-
tensity was the sum of the intensities for the split
peaks. In some spectra, peaks could not be seen. In
such cases, the peak intensity was set to the estimated
noise level in that spectrum. That noise level is evalu-
ated by searching for the maximum of the absolute
value of the intensity seen in a region devoid of real
signals.
When calculating percentage incorporations of 13C, it is
the natural abundance reference spectrum peak intensity
that may be missing. Substituting the dummy peak inten-
sity tends to cause the percentage incorporation of 13C to
be (conservatively) underestimated.
Malonate spiking
For spiking, a sample from a BaP-treated HL60 or K562
cell extract grown on unlabelled media was split into
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two. To the first sample, metabolomics buffer was
added. To the second sample, an equal amount of meta-
bolomics buffer containing 1 mM malonic acid was
added. 1H-1D and 1H-13C-HSQC spectra were acquired.
Spectra were aligned on TMSP and lactate, respectively,
for overlay in 1D and 2D spectra.
Results
We employed [1-13C]glucose, [1,2-13C]glucose and
[3-13C]glutamine nutrient sources to decipher the
carbon flow in K562 cells and changes in response
to BaP treatment. Overall, we observe the largest
amount of label incorporation into ribose moieties
and lactate (see [15] and Additional file 1: Figure S1
for details on label distributions). As illustrated in
Fig. 1, label incorporation into the Krebs cycle arising
from [1,2-13C]glucose can be expected to produce two
distinctly different labelling patterns of Krebs cycle metab-
olites depending upon whether the C2 fragment enters via
pyruvate carboxylase (PC) or pyruvate dehydrogenase
(PDH). The [2,3-13C]pyruvate formed from [1,2-13C]glu-
cose will yield [4,5-13C]glutamate via PDH, but
[2,3-13C]glutamate via PC activity. As PC activity produces
oxaloacetate from pyruvate, one expects [2,3-13C]malate
derived from PC, whereas the PDH product will be
[1,2-13C]malate or [3,4-13C]malate.
NMR spectra indicate that large amounts of aspartate and
malate are PC derived
As shown in Fig. 2, significant differences are observed
between cells processing [1,2-13C]glucose for 3 vs. 24 h
for the resonances of malate and aspartate. These differ-
ences manifest predominantly in a change of NMR-
coupling constants. The size of these coupling constant
depends on the nature of the adjacent carbon atom: a
carboxylic acid group yields a much larger coupling con-
stant than a CH2 group. The coupling constant for the
13C1
13C2 moiety in aspartate or malate is about 50–60 Hz
whereas the coupling constant for a 13C2
13C3 moiety is
about 35–40 Hz.
For a 24-h labelling period, Fig. 2 shows apparent
coupling constants of 53 Hz for C2 of malate and aspar-
tate. This large apparent coupling constant shows that
the coupling of C2 with the adjacent C1 carboxylic acid
group predominates. This 13C1
13C2 coupling pattern (and
also 13C3
13C4, see Additional file 1) arises from the PDH
activity and possibly also from metabolites passing
glucose
pyruvate acetyl-CoA
-KG/
glutamate
succinate
fumarate
oxaloacetateaspartate
malate
PDH
PC
citrate
PDH-derived
Label 
incorporation:
PC-derived
1 2
1 2 3
O-
O
O
CH31 2
3
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
1 2
1 2
3 4 5
1 2 3 4
Fig. 1 Label distribution arising from [1,2-13C]glucose via pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), respectively. For PDH
(red), label incorporation in a clockwise direction is assumed. For PC (blue) label incorporation is considered in an anti-clockwise direction, except for
clockwise labelling of glutamate. For the onward processing from α-ketoglutarate in a clockwise direction, the loss of C1 produces [1,2-13C]succinate
which is, owing to the symmetry of succinate, identical to the PDH-derived product
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multiple times through the Krebs cycle for longer label-
ling period.
For the short 3-h labelling period, the smaller apparent
coupling constants of 47 and 41 Hz are observed for C2
(Fig. 2 and Additional file 1: Figure S1), indicating that
the coupling to the adjacent methylene C3 dominates.
The presence of the 13C2
13C3 moiety at shorter labelling
periods shows that the product arising from the PC ac-
tivity dominates for shorter labelling periods.
It should be noted that the observed signal splittings
do not represent the precise scalar coupling constants in
a mixture of labelled compounds. Nevertheless, the ob-
served change provides a clear indication of higher
amounts of the PC product at shorter labelling periods
in both malate and aspartate.
Further evidence for PC activity in subspectra of uracil
In de novo pyrimidine synthesis, uracil is formed from
aspartate via carbamoyl-aspartate, orotate and dihy-
droorotate. Therefore, labelling patterns in aspartate
should be reflected in pyrimidine ring signals. Additional
file 2: Figure S2 shows expected label incorporations for
uracil. When the uracil base in UDP is synthesised from
aspartate, the destination of the 13Cs is as follows: C1, C2
and C3 of aspartate become respectively C10, C11 and
C12 of UDP while C4 is lost (see Additional file 2). In
HSQC spectra, only C11 and C12 are able to be directly
observed, as C10 does not have an attached proton.
For [1,2-13C]glucose-labelled samples the PC-derived
aspartate will be C2C3-labelled. This is converted to a la-
belled C11C12 fragment in UDP. However, PDH-derived
aspartate can be labelled at C1C2 or C3C4. This trans-
lates into C10C11 or an isolated C12 in uracil, respect-
ively. Therefore, spectra of C12 are indicative of relative
amounts of PC vs. PDH activity; PC yields a doublet for
C12, whereas PDH yields a singlet at C12.
All spectra showed both the singlet and doublet sig-
nals at C12 (Fig. 3). However, the intensity of the doublet
relative to the singlet changed between 3 and 24 h data
by a factor of three, again indicating a shift from PC to
PDH-mediated labelling with time. The picture that
emerges from several metabolites is that there is parallel
activity of both PC and PDH, but the PC product is pri-
marily channelled into products directly linked to oxalo-
acetate, yielding the high observed amount of PC
product into these metabolites in a short-term exposure.
Only at longer labelling periods is the PDH product ob-
served in the left branch of the Krebs cycle.
BaP-induced malonate is derived from downstream PC
activity in K562 cells
We have shown that malonate can be formed from oxa-
loacetate by chemical conversion under the influence of
hydrogen peroxide and suggested in our previous study
that malonate accumulation in response to BaP treat-
ment was driven by treatment-induced elevation of ROS
acting upon oxaloacetate [4]. Samples were spiked with
malonate to confirm our assignment of the malonate
methylene 1H/13C resonances in HSQC spectra (see
Additional files 3 and 4). Subsequently, in this study, our
tracer-based approach has allowed us to consider the or-
igins of the observed malonate.
As shown in Fig. 4a, ROS-derived malonate arising
from oxaloacetate that had been formed directly from
pyruvate by PC activity using [1,2-13C]glucose as the nu-
trient source would be expected to be labelled in posi-
tions C1 and C2. In the alternative situation that PDH
activity converts pyruvate into acetyl-coA upon entry
into the Krebs cycle, ROS-mediated conversion of the
resulting oxaloacetate into malonate would be expected
to give rise to two products with label in the C1 or in
the C1 and C2 position in a 1:1 ratio because the Krebs
cycle passes through symmetrical succinate and fumar-
ate (see also Fig. 1).
Figure 4b shows a representative 1D slice from HSQC
spectra arising from 24 h BaP-treated [1,2-13C]glucose-
labelled cells and clearly demonstrates drug-induced
generation of a strong malonate signal. In the corre-
sponding HSQC spectra arising from 24 h BaP-treated
[1,2-13C]glucose-labelled cells, we observed a clear
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Fig. 2 Sections from HSQC spectra for K562 cells labelled with
[1,2-13C]glucose showing peak splittings arising from the JCC
coupling. Spectra are shown for the HC2 atoms of aspartate and
malate at 3 and 24 h labelling, showing different sizes of apparent
coupling constants
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Fig. 3 Signals observed in [1,2-13C]glucose-labelled cells for UDP, showing different intensities (numbers besides signals) for 3 and 24 h labelled cells
Fig. 4 a Expected labelling patterns in malonate derived from oxaloacetate by decarboxylation and expected signal patterns in directly observed
13C spectra. b Slices from HSQC spectra for malonate for [1,2-13C]glucose-derived samples with (red) and without (blue) BaP treatment. c Peak
patterns observed for malonate in 1H-13C-HSQC spectra, red for [1,2-13C]glucose-labelled cells, blue for [1-13C]glucose-labelled cells. d 13C-NMR
spectra for the carboxylic acid region showing the spectrum arising from [1,2-13C]glucose with BaP in blue and the reference spectrum of unlabelled
malonate in red. The lack of a centre peak proves that 13COO is always adjacent to a labelled CH2. The asterisk denotes a non-malonate-derived
carbon atom
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doublet (Fig. 4c shown as red peaks) with a splitting of
58 Hz, indicative of a labelled CH2 group coupled to a
carboxylic acid carbon. This is a clear indication of a
C1,C2 (or C2,C3)-labelled malonate with label in only
one of the two carboxylic acid groups. Malonate labelled
in all three positions that might arise from multiple pas-
sages through the Krebs cycle would be expected to
show a triplet at the C2 in the
13C-dimension of HSQC
spectra, as at least some percentage would be labelled in
both COO groups (AX2 coupling pattern). Therefore,
the absence of a central signal in HSQC is highly indica-
tive that malonate is derived from upstream PC activity.
The absence of malonate derived from multiple Krebs
cycles and PDH activity is also supported by the fact that
malonate arising from 24 h labelling of BaP-treated cells
with [1-13C]glucose showed only a singlet (Fig. 4c shown
as blue peak).
In order to further prove that drug-induced malonate
is derived downstream of PC activity, we acquired 13C-
1D-spectra in which we could observe the COO reso-
nances of malonate directly (Fig. 4d). A reference
spectrum of 10 mM malonic acid in the same (pH 7)
buffer as used for cell extracts confirmed the frequency
of the COO resonance (Fig. 4d).
PC-mediated labelling is expected to yield a doublet at
C1 (arising from [1,2-
13C]malonate), whereas PDH-
mediated labelling is expected to give a 50:50 mixture of
a doublet arising from [1,2-13C]malonate and a singlet
arising from [1-13C]malonate (Fig. 4a). Although noisy
even after 24 h of acquisition, the spectra derived
showed a clear doublet with no residual signal in the
middle (Fig. 4d) confirming that the PC-derived labelling
product is dominant. From this, we conclude that mal-
onate is indeed derived from ROS-mediated conversion
of oxaloacetate originating entirely or at least predomin-
antly from the PC activity and does not show any contri-
bution from a possible PDH product even after a 24 h
labelling period. Control experiments using [3-13C]glu-
tamine as a carbon source showed only minimal label in-
corporation into malonate. The malonate produced from
[1,2-13C]glucose was shown to be predominantly labelled
via PC. Together, these two facts strongly suggest that
malonate is produced predominantly from glucose via
glycolysis and PC-mediated entry of pyruvate into the
TCA cycle.
Evidence of parallel PDH activity
Table 1 compares 1JCC coupling constants and multiplet
intensity patterns seen in the 3 and 24 h labelled data-
sets. In both the 3 and 24 h data sets, labelling at gluta-
mate’s C4 is much greater than the labelling at C4 and
the splitting seen at C4 indicates coupling to C5. This
strongly suggests that PDH-mediated labelling is domin-
ant for glutamate at both time points. The citrate C2 is
split by a large coupling to C1, again strongly suggesting
that PDH-mediated labelling is dominant. These label-
ling patterns indicate a clear dominance of PDH prod-
ucts for the right branch of the Krebs cycle, leading
from citrate to glutamate.
Computational multiplet analysis
Slices from the 1H-13C-HSQC were also quantitatively
analysed by simulating 13C-NMR spectra for a mixture
of different isotopomers using the pyGamma software
[21] from within the NMRLab software [19]. For glutam-
ate, the multiplet analysis confirmed that PDH-mediated
labelling was dominant at both 3 and 24 h irrespective
of BaP treatment. For aspartate, the multiplet analysis
confirmed that there was a shift from PC-mediated la-
belling at 3 h towards PDH-mediated labelling at 24 h.
The simulated spectra are shown in Additional file 5:
Figure S4, and Table 2 confirms qualitative results for
aspartate and glutamate.
Discussion
This study sheds further light on the action of ROS in
AML cell lines. The importance of ROS for the treat-
ment of leukaemic cancers has previously been
highlighted by us [4, 22] and by others [9–11]. Our pre-
vious study also showed that high levels of ROS are as-
sociated with chemical conversion of oxaloacetate into
malonate, and this phenomenon is common to a variety
of AML cell lines [4].
A number of studies, including some very recent re-
ports, have investigated PC activity in relation to cancer.
DeBerardinis and coworkers showed that PC takes over
as the alternative anaplerotic mechanism when glutami-
nolysis is silenced [23]. This is seen in the labelling pat-
tern obtained for glutamate C2 in tracer based metabolic
Table 1 Observed coupling constants in 1H-13C-HSQC spectra
3 h 24 h
Metabolite and atom at
which coupling is observed
Control BaP Control BaP
Aspartate 41:47:41 47:41:41 53:53:53 53:53:53
C2:C3a:C3b 1JCC/Hz
Malate 47:47:41 47:47:47 53:53:53 59:53:59
C2:C3a:C3b 1JCC/Hz
Fumarate C2 Singlet Singlet 70 70
1JCC/Hz
Succinate C2 53 59 59 59
1JCC/Hz
Glutamate 53:41:59 53:41:59 59:35:59 59:35:53
C2:C3:C4 1JCC/Hz
Citrate C2a:C2b 59:53 65:65 59 59
1JCC/Hz
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analyses using glioblastoma cell lines. PC has been
shown to be enhanced in human non-small cell lung
cancers in xenograft mouse models [24]. It has also been
shown that PC activity is high in human lung tumours
[16, 17, 25] and critical for cell proliferation and colony
formation in human non-small cell lung cancer cells
[18]. Likewise, Phannasil et al. showed that PC was up-
regulated in breast cancer tissues, PC expression was
higher in cell lines with greater metastatic potential, and
that proliferation, migration and in vitro invasion ability
is PC dependent [26]. Recent work shows that pyruvate
carboxylation diverts glucose-derived carbons into aspar-
tate biosynthesis in succinate dehydrogenase (SDH)-ab-
lated kidney mouse cells [27]. In analogy to non-small
cell lung cancers, we also observe high PC activity in the
AML K562 cell line.
The patterns of metabolite labelling we observed and
the kinetics of their changes with time lead us to con-
clude that the Krebs cycle is disrupted in K562 cells. We
have clearly demonstrated the branched uptake of pyru-
vate into the cycle via ‘left-hand’ PC-mediated and
‘right-hand’ PDH-mediated entry. The PC-mediated
entry was readily observed at smaller labelling periods
(3 h). At this time, the conversion of PDH products in
the right-hand branch of the Krebs cycle into malate and
aspartate was low but became more evident at 24 h.
However, continued PC-mediated entry to the Krebs
cycle even at longer flux periods was confirmed by the
origin of malonate following BaP treatment. Our earlier
study identified malonate accumulation in response to
BaP. However, [1-13C]glucose and [1,2-13C]glucose trace
labelling approaches have demonstrated that this malon-
ate unexpectedly originates almost exclusively from PC-
derived oxaloacetate.
The generation of malonate in response to BaP treat-
ment, in turn appears to drain the pool of oxaloacetate
being formed from PC activity. At the same time, the ac-
cumulated malonate, which is known to block the SDH
activity, appears to further disrupt the Krebs cycle as evi-
denced by a twofold reduction in the fumarate/succinate
ratio following BaP treatment.
Importantly, we did not observe any visible contribu-
tion to the malonate pool from any PDH-derived prod-
ucts after one or several complete passages through the
Krebs cycle providing remarkable evidence of direct con-
version of oxaloacetate to malonate at the site of its for-
mation by PC.
Whether the mechanisms described here require spe-
cific niche conditions, such as those in peripheral blood,
cannot be answered from the existing study. Preclinical
studies of BaP anti-cancer activities were demonstrated
in non-hypoxic cultures [8] and translated to clinical ef-
ficacy in vivo including haematological responses as well
as reduction in tumour load [7, 8]. As malonate forma-
tion under high ROS has been observed in several AML
cell lines and can be reproduced by treatment of cell ex-
tracts in vitro [4], we suggest that the role of malonate
may be common to any cell when ROS is sufficiently
high.
Conclusions
In a wider context, this study indicates that in the case
of AML cells, malonate represents a marker of increased
ROS, an observation that needs investigation in other
cancer models. This is also important for the wider ap-
plication of our findings for cancer treatments. As dis-
cussed above, there are a growing number of
observations indicating that PC activity underpins the
neoplastic characteristics of several cancers. Using BaP
here as an example, we have shown that the PC activity
of cancer cells can be exploited, as an Achilles heel, by
fuelling ROS-generated production of malonate. On a
broader perspective in cancer, this in turn has implica-
tions for the development of malonate derivatives as po-
tential cancer therapeutics.
Additional files
Additional file 1: Figure S1. Peak patterns observed for aspartate HC2
and HC3. Sections from HSQC spectra for K562 cells labelled with
[1,2-13C]glucose showing peak splittings arising from the JCC coupling.
Spectra are shown for the HC2 and HC3 atoms of aspartate at 3 and 24 h
labelling, showing different sizes of apparent coupling constants.
(PDF 1.03 mb)
Additional file 2: Figure S2. Label incorporation into pyrimidines.
Label distribution arising from [1,2-13C]glucose via pyruvate
dehydrogenase (PDH) in red; from [1,2-13C]glucose via pyruvate
carboxylase (PC) in purple; and from [3-13C]glutamine in green,
respectively. Note that the PDH route produces an isolated 13C at C12 in
UDP. (PDF 1.03 mb)
Additional file 3: Figure S3A. Malonate spiked sample. An unlabelled
cell extract was split into two, and to one sample, buffer containing
Table 2 Percentages of isotopomers arising from a
computational multiplet analysis
3 h Labelling
Control BaP treated
Asp %PDH %PC %PDH %PC
1.28 ± 0.08 2.11 ± 0.04 1.52 ± 0.17 2.25 ± 0.11
Glu %PDH %PC %PDH %PC
2.99 ± 0.04 0.64 ± 0.04 4.63 ± 0.07 0.68 ± 0.09
24 h labelling
Control BaP treated
Asp %PDH %PC %PDH %PC
3.17 ± 0.31 0.86 ± 0.08 2.62 ± 0.15 1.03 ± 0.17
Glu %PDH %PC %PDH %PC
4.42 ± 0.14 0.66 ± 0.08 5.32 ± 0.29 0.58 ± 0.06
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malonate acid was added, and to the other sample, an equal volume of
buffer was added. Regions from the resulting 1H NMR spectra for the
original and spiked samples are overlaid in blue and red, respectively.
(PDF 1.03 mb)
Additional file 4: Figure S3B. Malonate spiked sample. An unlabelled
cell extract was split into two, and to one sample, buffer containing
malonic acid was added and the pH adjusted to 7, and to the other
sample, an equal volume of buffer was added. The regions of the
resulting HSQC spectra containing the malonate and lactate resonances
for the original and spiked samples are overlaid in blue and red,
respectively. Lactate is shown as a sensitivity reference. (PDF 1.03 mb)
Additional file 5: Figure S4. Simulation of spectral multiplets arising
from 1H-13C-HSQC spectra for aspartate and glutamate. (PDF 383 kb)
Abbreviations
AML, acute myeloid leukaemia; BaP, bezafibrate and medroxyprogesterone;
BL, Burkitt’s lymphoma; HSQC, heteronuclear single quantum coherence; PC,
pyruvate carboxylase; PDH, pyruvate dehydrogenase; ROS, reactive oxygen
species; SDH, succinate dehydrogenase
Acknowledgements
MR was in part supported by the COSMOS EU grant (FP7-INFRASTRUCTURES-
2012-1-312941. FK and CB were supported by a Bloodwise (formerly called
Leukaemia & Lymphoma Research (LLR)) Specialist Programme. We also
thank the Wellcome Trust for supporting the HWB-NMR facility where all the
NMR work was carried out.
Authors’ contributions
MR acquired and analysed data and helped to write and revise the
manuscript. CL developed methodology and analysed data. FK was involved
in the study conception and design, data acquisition, and writing and
revising the manuscript. CB was involved in the study conception and
design and in writing and revising the manuscript. UG supervised the project
and was involved in the conception and design of the study, methodology
development, analysis of data, and writing and revision of the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Institute of Cancer and Genomic Sciences, University of Birmingham,
Birmingham B15 2TT, UK. 2School of Biosciences, University of Birmingham,
Birmingham B15 2TT, UK. 3Institute of Metabolism and Systems Research,
University of Birmingham, Birmingham B15 2TT, UK.
Received: 21 January 2016 Accepted: 1 July 2016
References
1. Bunce CM, Mountford JC, French PJ, Mole DJ, Durham J, Michell RH, et al.
Potentiation of myeloid differentiation by anti-inflammatory agents, by
steroids and by retinoic acid involves a single intracellular target, probably
an enzyme of the aldoketoreductase family. Biochim Biophys Acta BBA-Mol
Cell Res. 1996;1311:189–98.
2. Scatena R, Nocca G, De Sole P, Rumi C, Puggioni P, Remiddi F, et al.
Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell
Death Differ. 1999;6:781–7.
3. Nilsson A, Farrants AK, Nesland JM, Finstad HS, Pedersen JI. Potentiating
effects of clofibric acid on the differentiation of HL-60 human promyelocytic
leukemia cells induced by retinoids. Eur J Cell Biol. 1995;67:379–85.
4. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, Günther UL. Metabolomic
profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One.
2009;4:e4251. Cordes N, editor.
5. Fenton SL, Luong QT, Sarafeim A, Mustard KJW, Pound J, Desmond JC, et al.
Fibrates and medroxyprogesterone acetate induce apoptosis of primary
Burkitt’s lymphoma cells and cell lines: potential for applying old drugs to a
new disease. Leukemia. 2003;17:568–75.
6. Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, et al.
Treatment of primary CLL cells with bezafibrate and medroxyprogesterone
acetate induces apoptosis and represses the pro-proliferative signal of
CD40-ligand, in part through increased 15dD12,14, PGJ2. Leukemia.
2008;23:292–304.
7. Murray JA, Khanim FL, Hayden RE, Craddock CF, Holyoake TL, Jackson N, et
al. Combined bezafibrate and medroxyprogesterone acetate have efficacy
without haematological toxicity in elderly and relapsed acute myeloid
leukaemia (AML). Br J Haematol. 2010;149:65–9.
8. Molyneux E, Merrick B, Khanim FL, Banda K, Dunn JA, Iqbal G, et al.
Bezafibrate and medroxyprogesterone acetate in resistant and relapsed
endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2
study (ISRCTN34303497). Br J Haematol. 2014;164:888–90.
9. Abdel-Wahab O, Levine RL. Metabolism and the leukemic stem cell. J Exp
Med. 2010;207:677–80.
10. Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al.
Targeting iron homeostasis induces cellular differentiation and synergizes
with differentiating agents in acute myeloid leukemia. J Exp Med.
2010;207:731–50.
11. Nogueira-Pedro A, Cesário TAM, Dias CC, Origassa CST, Eça LPM, Paredes-Gamero
EJ, et al. Hydrogen peroxide (H2O2) induces leukemic but not normal
hematopoietic cell death in a dose-dependent manner. Cancer Cell Int. 2013;13:1.
12. Fedotcheva NI, Sokolov AP, Kondrashova MN. Nonezymatic formation of
succinate in mitochondria under oxidative stress. Free Radic Biol Med.
2006;41:56–64.
13. Brookes PS, Freeman RS, Barone MC. A shortcut to mitochondrial signaling
and pathology: a commentary on “nonenzymatic formation of succinate in
mitochondria under oxidative stress.”. Free Radic Biol Med. 2006;41:41–5.
14. Potter VR, DuBois KP. Studies on the mechanism of hydrogen transport in
animal tissues: VI. Inhibitor studies with succinic dehydrogenase. J Gen
Physiol. 1943;26:391.
15. Carrigan JB, Reed MAC, Ludwig C, Khanim FL, Bunce CM, Günther UL.
Tracer-Based metabolic NMR-based flux analysis in a leukaemia cell line.
ChemPlusChem. 2016;81(5):453–459.
16. Lane AN, Fan TW-M, Bousamra M, Higashi RM, Yan J, Miller DM. Stable
isotope-resolved metabolomics (SIRM) in cancer research with clinical
application to nonsmall cell lung cancer. OMICS J Integr Biol. 2011;15:173–82.
17. Lane AN, Fan TW-M, Higashi RM, Tan J, Bousamra M, Miller DM. Prospects
for clinical cancer metabolomics using stable isotope tracers. Exp Mol
Pathol. 2009;86:165–73.
18. Sellers K, Fox MP, Bousamra M, Slone SP, Higashi RM, Miller DM, et al.
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.
J Clin Invest. 2015;125:687–98.
19. Günther UL, Ludwig C, Rüterjans H. NMRLAB—advanced NMR data
processing in Matlab. J Magn Reson. 2000;145:201–8.
20. Ludwig C, Günther UL. MetaboLab-advanced NMR data processing and
analysis for metabolomics. BMC Bioinformatics. 2011;12:366.
21. Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in
magnetic resonance. An object-oriented programming approach. J Magn
Reson A. 1994;106:75–105.
22. Khanim FL, Hayden RE, Birtwistle J, Lodi A, Tiziani S, Davies NJ, et al. Combined
Bezafibrate and medroxyprogesterone acetate: potential novel therapy for
acute myeloid leukaemia. PLoS One. 2009;4:e8147. Goodyear M, editor.
23. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate
carboxylase is required for glutamine-independent growth of tumor cells.
Proc Natl Acad Sci. 2011;108:8674–9.
24. Fan TW-M, Lane AN, Higashi RM, Yan J. Stable isotope resolved metabolomics
of lung cancer in a SCID mouse model. Metabolomics. 2010;7:257–69.
25. Lane AN, Fan TW-M, Higashi RM. Stable isotope-assisted metabolomics in
cancer research. IUBMB Life. 2008;60:124–9.
26. Phannasil P, Thuwajit C, Warnnissorn M, Wallace JC, MacDonald MJ,
Jitrapakdee S. Pyruvate carboxylase is up-regulated in breast cancer and
essential to support growth and invasion of MDA-MB-231 cells. PLoS One.
2015;10:e0129848. Singh PK, editor.
27. Cardaci S, Zheng L, MacKay G, van den Broek NJF, MacKenzie ED, Nixon C,
et al. Pyruvate carboxylation enables growth of SDH-deficient cells by
supporting aspartate biosynthesis. Nat Cell Biol. 2015;17:1317–26.
Reed et al. Cancer & Metabolism  (2016) 4:15 Page 8 of 8
